1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Physician Views: Secondary warehousing begins in Hep C market in anticipation for all-oral combinations – who is driving this trend?

Physician Views: Secondary warehousing begins in Hep C market in anticipation for all-oral combinations – who is driving this trend?

  • June 2014
  • ID: 3509524
  • Format: PDF
  • Firstword Pharma

Summary






Sales of Gilead Sciences' hepatitis C treatment Sovaldi have blown away pre-launch expectations since the product became available in the US in December. Its level of initial usage was severely underestimated, particularly among genotype 1 patients (either in combination with interferon, without interferon but over a longer duration of therapy and in combination with Johnson & Johnson's Olysio), which have accounted for approximately 70 percent of use to date, according to Gilead.

See Physician Views Poll Results – Gilead Sciences' sofosbuvir could take significant share of warehoused HCV population prior to launch of interferon-free regimens and Spotlight On: History in the making – How does Gilead manage lofty Sovaldi expectations?

Despite this impressive launch – which is projected to drive annual sales to around $9 billion, according to current consensus estimates – the real revolution in hepatitis C is expected to occur in the fourth quarter when Gilead gains approval for its Sovaldi plus ledipasvir combination therapy (the company has been granted a PDUFA date of October 10). This product will allow many hepatitis C patients to be treated over a 12-week period without the requirement of either interferon or ribavirin.

Recent US prescription data for Sovaldi – which shows a flat-lining of new usage – indicates that anticipation levels for this new all-oral regimen (and another being developed by AbbVie which is expected to gain FDA approval by year end) are on the rise. A secondary phase of patient warehousing for these drugs is now occurring, says ISI analyst Mark Schoenebaum. See ViewPoints: Secondary warehousing starts to bite into Sovaldi sales.

This trend has been expected, adds Schoenebaum, although it is fair to say that the aggressive response among US payers (and some politicians) to the initial influx of patients seeking treatment with Sovaldi has shifted the dynamic of the future hepatitis C market somewhat.

Sovaldi's initial success may have had some impact not only on the number of patients now being warehoused for usage with all-oral combinations, but could dictate the speed at which these patients are treated as payers look to better manage their cost structures.









With these factors in mind, FirstWord is polling US based specialists in the hepatitis C physician setting to ascertain both how aggressively they are now warehousing patients and whether they are under increased pressure to do so. Specifically we are asking them...


What percentage of genotype 1 hepatitis C patients they are currently warehousing (i.e. are diagnosed but not being treated)?
What percentage of these patients they expect to treat with the fixed-dose combination of Sovaldi plus ledipasvir within six months of its launch?
How they expect (from a volume perspective) the initial six-month uptake of Gilead's Sovaldi plus ledipasvir fixed-dose combination to compare to the initial six-month uptake of Sovaldi?
How they assess the current level of 'enforced' patient warehousing/delayed therapy for patients due to pressure from Medicaid providers?
How they assess the current level of 'enforced' patient warehousing/delayed therapy for patients due to pressure from pharmacy benefit managers (PBMs)?





Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Global Viral Hepatitis and Retrovirus Diagnostic Tests Industry

  • $ 4950
  • April 2021
  • 127 pages

Abstract: - Global Viral Hepatitis and Retrovirus Diagnostic Tests Market to Reach $5.9 Billion by 2027 - Amid the COVID-19 crisis, the global market for Viral Hepatitis and Retrovirus Diagnostic Tests ...

  • World
  • China
  • Hepatitis
  • HIV AIDS
  • Industry analysis

ref:plp2014

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on